sur NanoViricides, Inc. (NASDAQ:NNVC)
NanoViricides to Present Breakthrough Antiviral Developments at Biotech Showcase
NanoViricides, Inc., a clinical-stage company specializing in broad-spectrum antiviral drugs, will present at the Biotech Showcase 2025 in San Francisco on January 14. The company aims to provide updates on its drug pipeline and technologies available for licensing.
Dr. Anil R. Diwan, President and Executive Chairman, will discuss the promising drug candidate NV-387, which has shown potential against a variety of viral infections. NV-387 mimics a host-site feature exploited by many human viruses, potentially preventing them from escaping treatment.
NV-387 has exhibited superior activity compared to existing drugs in treating viral infections like Influenza A, MPox, Smallpox, RSV, and COVID-19 in animal models. The market value for NV-387 treatments exceeds $10 billion.
Biotech Showcase, concurrent with the JP Morgan Life Sciences Conference, provides a platform for companies to network with investors and executives, fostering future partnerships and investment opportunities.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de NanoViricides, Inc.